Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028447615> ?p ?o ?g. }
- W2028447615 endingPage "47" @default.
- W2028447615 startingPage "47" @default.
- W2028447615 abstract "Profile of pegvisomant in the management of acromegaly: an evidence based review of its place in therapy Ignacio Bernabeu,1 Iria Adriana Rodriguez-Gomez,2 Ana Maria Ramos-Levi,3 Monica Marazuela3 1Department of Endocrinology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; 2Endocrine Unit, Hospital HM Modelo, A Coruña, Spain; 3Department of Endocrinology, Hospital Universitario de la Princesa, Instituto de Investigación Princesa, Universidad Autónoma de Madrid, Madrid, Spain Abstract: Pegvisomant (PEG) is a genetically engineered growth hormone (GH) analog able to bind and block the GH receptor. PEG blocks all metabolic effects of GH hypersecretion, normalizes insulin-like growth factor I (IGF-I) level and paradoxically produces an increase in GH secretion. When PEG was commercialized, there were some concerns regarding whether the increased GH secretion could cause growth of the residual tumor or cause the overcoming of receptor blockade with loss of efficacy. PEG commercialization was followed by the onset of two main prospective observational studies aiming to evaluate the safety and outcome of PEG long-term treatment: the German Pegvisomant Observational Study and ACROSTUDY. These observational studies, along with several independent studies have provided comprehensive information regarding the actual use, efficacy and safety of long-term treatment with PEG. The efficacy of PEG in clinical setting is somewhat lower than that reported in the pivotal studies, nevertheless PEG normalizes IGF-I levels ranging between 65% and 97% of cases. Side effects in observational studies were uncommon and rarely caused discontinuation of treatment. Liver dysfunction developed in 2.5% of cases, was usually transient and no permanent liver damage was reported. Increased tumor size was developed by about 2.2%–3.2% of acromegalic patients treated with PEG, without differences to that described for other modalities of treatment. Only one third of cases corresponded with true growth after initiation of PEG treatment. Involved mechanism is currently unknown. New modalities of treatments by the combined use of PEG with somatostatin analog or cabergoline have been developed with promising results. Recently, two clinical guidelines written to optimize the use of these treatment modalities and to monitor possible adverse events have been published. Keywords: acromegaly, pegvisomant, pituitary tumor, somatostatin analogs, cabergoline, IGF-I" @default.
- W2028447615 created "2016-06-24" @default.
- W2028447615 creator A5044905998 @default.
- W2028447615 creator A5047448393 @default.
- W2028447615 creator A5067149370 @default.
- W2028447615 creator A5082184611 @default.
- W2028447615 date "2015-02-01" @default.
- W2028447615 modified "2023-09-27" @default.
- W2028447615 title "Profile of pegvisomant in the management of acromegaly: an evidence based review of its place in therapy" @default.
- W2028447615 cites W123434114 @default.
- W2028447615 cites W175401376 @default.
- W2028447615 cites W1968686660 @default.
- W2028447615 cites W1969427273 @default.
- W2028447615 cites W1969570257 @default.
- W2028447615 cites W1972884512 @default.
- W2028447615 cites W1975128137 @default.
- W2028447615 cites W1975680180 @default.
- W2028447615 cites W1981095970 @default.
- W2028447615 cites W1983950740 @default.
- W2028447615 cites W1985791167 @default.
- W2028447615 cites W1986210032 @default.
- W2028447615 cites W1986423215 @default.
- W2028447615 cites W1988158211 @default.
- W2028447615 cites W1993154503 @default.
- W2028447615 cites W1993567990 @default.
- W2028447615 cites W1999552666 @default.
- W2028447615 cites W2000909542 @default.
- W2028447615 cites W2004483751 @default.
- W2028447615 cites W2004572394 @default.
- W2028447615 cites W2010961613 @default.
- W2028447615 cites W2014018805 @default.
- W2028447615 cites W2019813896 @default.
- W2028447615 cites W2021983698 @default.
- W2028447615 cites W2022761818 @default.
- W2028447615 cites W2024054676 @default.
- W2028447615 cites W2027423344 @default.
- W2028447615 cites W2037226702 @default.
- W2028447615 cites W2040469092 @default.
- W2028447615 cites W2044785613 @default.
- W2028447615 cites W2045942594 @default.
- W2028447615 cites W2052968879 @default.
- W2028447615 cites W2056451367 @default.
- W2028447615 cites W2057224144 @default.
- W2028447615 cites W2063487518 @default.
- W2028447615 cites W2063504164 @default.
- W2028447615 cites W2066796088 @default.
- W2028447615 cites W2068704610 @default.
- W2028447615 cites W2073150765 @default.
- W2028447615 cites W2073260445 @default.
- W2028447615 cites W2079774691 @default.
- W2028447615 cites W2080232093 @default.
- W2028447615 cites W2080846291 @default.
- W2028447615 cites W2086782730 @default.
- W2028447615 cites W2093085149 @default.
- W2028447615 cites W2095098627 @default.
- W2028447615 cites W2097793173 @default.
- W2028447615 cites W2099181842 @default.
- W2028447615 cites W2100615084 @default.
- W2028447615 cites W2101992531 @default.
- W2028447615 cites W2106242215 @default.
- W2028447615 cites W2107244929 @default.
- W2028447615 cites W2107724413 @default.
- W2028447615 cites W2108583295 @default.
- W2028447615 cites W2111584950 @default.
- W2028447615 cites W2113464653 @default.
- W2028447615 cites W2114461739 @default.
- W2028447615 cites W2115465228 @default.
- W2028447615 cites W2117099801 @default.
- W2028447615 cites W2118468197 @default.
- W2028447615 cites W2120166425 @default.
- W2028447615 cites W2121326610 @default.
- W2028447615 cites W2122845310 @default.
- W2028447615 cites W2123997600 @default.
- W2028447615 cites W2126132809 @default.
- W2028447615 cites W2128988809 @default.
- W2028447615 cites W2131936635 @default.
- W2028447615 cites W2136266310 @default.
- W2028447615 cites W2138068788 @default.
- W2028447615 cites W2139121959 @default.
- W2028447615 cites W2139926910 @default.
- W2028447615 cites W2143791513 @default.
- W2028447615 cites W2147047572 @default.
- W2028447615 cites W2147795491 @default.
- W2028447615 cites W2149033923 @default.
- W2028447615 cites W2149789254 @default.
- W2028447615 cites W2151656934 @default.
- W2028447615 cites W2153200944 @default.
- W2028447615 cites W2153824679 @default.
- W2028447615 cites W2155465275 @default.
- W2028447615 cites W2158629056 @default.
- W2028447615 cites W2161634174 @default.
- W2028447615 cites W2169376102 @default.
- W2028447615 doi "https://doi.org/10.2147/rred.s78255" @default.
- W2028447615 hasPublicationYear "2015" @default.
- W2028447615 type Work @default.
- W2028447615 sameAs 2028447615 @default.
- W2028447615 citedByCount "4" @default.
- W2028447615 countsByYear W20284476152015 @default.